Scientific harassment by pharmaceutical companies: time to stop

Hailey, David
January 2000
CMAJ: Canadian Medical Association Journal;1/25/2000, Vol. 162 Issue 2, p212
Academic Journal
Focuses on the need to stop the scientific harassment by pharmaceutical companies. How the results of applied medical research funded by the private sector, are being released only selectively to the public; Dangerous trend of reporting only the favorable results of a study; Need for trials to register before they are carried out and make all results available for publication; How scientific government panels should be encouraged to submit reports of drugs and devices for peer review.


Related Articles

  • Fraud and misconduct in clinical research: A concern. Gupta, Ashwaria // Perspectives in Clinical Research;Apr-Jun2013, Vol. 4 Issue 2, p144 

    Fraud and misconduct in clinical research is widespread. Good clinical practice is a guideline adopted internationally as standard operating procedure for conduct of clinical research. Despite these guidelines being available, unavailability of internationally harmonized framework for managing...

  • A Hercule Poirot of clinical research. Sakamoto, Junichi // Gastric Cancer;Jan2016, Vol. 19 Issue 1, p21 

    The author comments on the lack of oversight of randomized clinical trials which has occasionally led to investigator misconduct. Topics covered include the failure to standardize rules for the conduct of post-marketing trials, a case of data fabrication in Japan disclosed by a whistleblower in...

  • Doctored results. Kippen, A. // Washington Monthly;Oct90, Vol. 22 Issue 9, p38 

    Examines some of the shady practices going on between doctors, medical journals and drug companies. Surgical incentives; Pharmaceutical sales; Honoraria based on drug prescriptions; Drug company supplements in medical journals; Medical symposia.

  • Wisconsin finds some price discrimination.  // Drug Topics;8/7/95, Vol. 139 Issue 15, p7 

    Reports on a Wisconsin study which found evidence that some manufacturers and wholesalers may be granting illegal discounts to hospital and health maintenance organization (HMO) pharmacies.

  • Full court press coming on short Rxs.  // Drug Topics;2/16/98, Vol. 124 Issue 4, p7 

    Reports that there will be investigations on drugstores in the United States which charge full fees for short-filled prescriptions. Reference to a lawsuit in Florida filed against Eckerd; Identification of other companies involved in this practice.

  • How R.Ph.s can avoid being taken in by scam artists. McCann, Jean // Drug Topics;2/16/98, Vol. 124 Issue 4, p80 

    Presents a look at how R.Ph.s can avoid being taken in by scam artists. Views from Ronald Buzzeo, a pharmacist-consultant who worked for the Drug Enforcement Administration for years, on scammers in search of controlled substances; Comments made by Buzzeo during the Second Conference on Pain...

  • The other drug lords.  // Common Cause Magazine;Fall92, Vol. 18 Issue 3, p8 

    Examines the power of the pharmaceutical industry and its lobbyists to control the fate of drug-related reforms and other legislation in Congress. Defeat of Arkansas Senator David Pryor's amendment to cut a tax break enjoyed by drug companies with factories in Puerto Rico; Price gouging; Drug...

  • The other drug war here at home.  // U.S. News & World Report;9/11/89, Vol. 107 Issue 10, p11 

    Discusses the battle between brand-name pharmaceutical companies and the generic-drug industry. Food and Drug Administration probe into generic-drug products; Scandal; Costs.

  • Peddling data. Conlan, Michael F. // Drug Topics;10/10/94, Vol. 138 Issue 19, p103 

    Reports on the collection of product prescription information and drugstore pricing policies by software companies for sale to interest groups in the pharmaceutical industry.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics